InspireMD, Inc.
NSPR Nasdaq· Surgical & Medical Instruments & Apparatus
Last close · Oct 27, 2026
$0.46
KIRA · Stoqly’s AI analyst, in plain words
- InspireMD, Inc. had $9.0M of revenue in fiscal 2025, up 28.1% on the year before. Over five years, revenue changed +29.3% a year on average.
- Its operating margin was −552.6%, down 74.6 pts: of every 100 in sales, about −553 is left after running the business.
- InspireMD, Inc. lost $48.8M in fiscal 2025.
- Free cash flow was −$36.8M in fiscal 2025, −409.5% of revenue.
Market cap
$38.5M
P/E
—
Revenue
$9.0M
Net income
−$48.8M
Free cash flow
−$36.8M
Operating margin
−552.6%
InspireMD, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+28.1%
Yes. Sales grew 28.1% last year.
Does it make a profit?
−543.3%
No. It lost money last year.
Does profit turn into cash?
−409.5%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 8
Weak. It passes 3 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What InspireMD, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 18, 2026
- Legal name
- InspireMD, Inc.
- CIK
- 0001433607
InspireMD, Inc. · NSPR
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $4.5M | $5.2M | $6.2M | $7.0M | $9.0M |
| Revenue growth | 80.9% | 15.0% | 20.0% | 13.0% | 28.1% |
| Gross margin | 16.8% | 21.6% | 29.1% | 21.5% | 29.5% |
| Operating margin | −327.4% | −361.9% | −340.7% | −478.0% | −552.6% |
| Net income | −$14.9M | −$18.5M | −$19.9M | −$32.0M | −$48.8M |
| Net margin | −331.9% | −357.6% | −321.0% | −456.6% | −543.3% |
| Diluted EPS | −$2.03 | −$2.35 | −$0.82 | −$0.76 | −$0.76 |
| Cash | |||||
| Cash from operations | −$13.2M | −$15.5M | −$16.4M | −$21.9M | −$35.1M |
| Capital expenditure | $0.3M | $0.5M | $0.4M | $1.4M | $1.7M |
| Free cash flow | −$13.6M | −$16.0M | −$16.8M | −$23.3M | −$36.8M |
| FCF margin | −301.5% | −309.7% | −270.1% | −332.0% | −409.5% |
| Share count change | 385.7% | 7.2% | 208.3% | 72.8% | 53.4% |
| Debt and strength | |||||
| Cash and short-term investments | $12.0M | $4.6M | $39.0M | $34.6M | $54.2M |
| Shareholders' equity | $33.5M | $17.4M | $39.5M | $36.1M | $55.2M |
| Current ratio | 8.5x | 4.2x | 7.3x | 5.3x | 5.7x |
| Returns and quality | |||||
| Return on equity | −65.3% | −72.6% | −70.0% | −84.7% | −106.9% |
| Return on tangible equity | −44.5% | −106.3% | −50.4% | −88.7% | −88.4% |
| Piotroski F-score | 4 | 3 | 4 | 2 | 3 |
| Altman Z'' | −6.4 | −24.9 | −7.8 | −14.3 | −10.1 |
Insiders bought, 12 months
$0.4M
4 insiders
Insiders sold, 12 months
$0.1M
1 insider
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
InspireMD, Inc. · NSPR
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.46 a share, the company is worth $38.5M.
Source: SEC EDGAR XBRL filings (CIK 0001433607). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.